ArticleCellular oncology (Dordrecht, Netherlands)2017

Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.

Felix H Shek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.